Physician profile
Douglas Orton
NPI 1346249935
$12,244.07
in general payments reported to CMS, 2019-2025
28 companies · $2,220 in 2025
The $2,220 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,436 · 2020: $889 · 2021: $1,933 · 2022: $1,293 · 2023: $1,500 · 2024: $1,972 · 2025: $2,220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,692.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,464.26 | 2022-2025 | Hydrus Microstent, Rocklatan, Tryptyr |
| Bausch & Lomb Americas INC. | $1,455.32 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Aerie Pharmaceuticals, INC. | $1,405.23 | 2019-2021 | |
| Allergan, INC. | $708.47 | 2019-2022 | |
| Eyevance Pharmaceuticals LLC | $585.00 | 2019-2022 | |
| Ivantis, INC | $575.45 | 2020-2021 | |
| Glaukos Corporation | $540.13 | 2023-2025 | Idose, Radius, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $532.55 | 2019-2021 | |
| Abbvie INC. | $526.10 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $488.59 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $448.48 | 2023-2024 | Omni Surgical System, Tearcare System |
| Kala Pharmaceuticals, INC. | $412.19 | 2021 | |
| Novartis Pharmaceuticals Corporation | $402.25 | 2019-2021 | |
| Oyster Point Pharma, INC. | $378.23 | 2022-2023 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $352.27 | 2020-2024 | Acthar |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $320.72 | 2019-2025 | |
| Harrow Eye, LLC | $272.03 | 2025 | Vevye |
| Astellas Pharma US INC | $256.08 | 2023-2024 | Izervay |
| Dompe US, INC. | $226.79 | 2019-2022 | |
| Shire North American Group INC | $147.33 | 2019 | |
| Mallinckrodt Enterprises LLC | $139.97 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $122.26 | 2019 | |
| Amgen INC. | $121.83 | 2025 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $115.48 | 2019-2022 | |
| Thea Pharma INC. | $108.17 | 2025 | Iyuzeh |
| Horizon Therapeutics Plc | $73.31 | 2022-2023 | Tepezza |
| Ani Pharmaceuticals, INC. | $46.32 | 2022-2023 | Purified Cortrophin Gel |
| Biotissue Holdings INC. | $19.26 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Orton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.